Eli Lilly and Company Limited

Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL
Telephone: +44 (0)1256 315 000
Fax: +44 (0)1256 775 858
WWW: http://www.lilly.co.uk
Medical Information e-mail: ukmedinfo@lilly.com
Customer Care direct line: +44 (0)1256 315 999
Medical Information Fax: +44 (0)1256 775 569
Patient Information Leaflet last updated on the eMC: 27/02/2009
PIL Alimta 100mg/500mg powder for concentrate for solution for infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 27/02/2009 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 02/05/2008 and displayed until 27/02/2009
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to side-effects
  • Changes to therapeutic indications
Updated on 06/02/2008 and displayed until 02/05/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
  • Change of special precautions for disposal
Updated on 02/04/2007 and displayed until 06/02/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Improved Electronic Presentation
  • Change to date of revision
Updated on 08/03/2007 and displayed until 02/04/2007
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Change to side-effects
  • Change to date of revision
Updated on 14/03/2006 and displayed until 08/03/2007
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 05/11/2004 and displayed until 14/03/2006
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   pemetrexed


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk